free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Basic Info

  • Grade: Pharmaceutical Grade

    Factory Location: Hubei

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Payment Terms: L/C

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.

Send your message to this supplier
  • From:
  • To:
    Shenzhen Haorui Pharmatech Co., Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service